7. (New) The method of Claim 5, wherein said brain disorder is cerebral vasospasm.

8. (New) The method of Claim 5, wherein said brain disorder is cerebral vasospasm associated with subarachnoid hemorrhage.

9. (New) The method of Claim 5, wherein said NF-κB decoy is a nucleic acid or an analog thereof that antagonizes the binding of nucleic acids to NF-κB.

10. (New) The method of Claim 5, wherein said NF-κB decoy is a single-stranded nucleic acid or nucleic acid analog.

11. (New) The method of Claim 5, wherein said NF-κB decoy is a double-stranded nucleic acid or nucleic acid analog.

12. (New) The method of Claim 5, wherein said NF-κB decoy is a cyclic nucleic acid or nucleic acid analog.

13. (New) The method of Claim 5, wherein said NF-κB decoy is DNA.

B1 cont

14. (New) The method of Claim 5, wherein said NF-κB decoy is a modified nucleotide or a pseudonucleotide.

15. (New) The method of Claim 5, wherein said NF-κB decoy is an S-oligonucleotide.

16. (New) The method of Claim 5, wherein said NF-κB decoy comprises multiple units of a nucleotide or nucleotide analog.

17. (New) The method of Claim 5, wherein said NF-κB decoy comprises SEQ ID NO: 1.

18. (New) A liposome comprising an NF-κB decoy, which inhibits the activation of at least one gene by the NF-κB transcription factor.

19. (New) The liposome of Claim 18 that comprises a cationic lipid.

20. (New) The liposome of Claim 18 that comprises a membrane-fusion promoter.

21. (New) The liposome of Claim 18 that comprises a large unilamellar vesicle (LUV) structure.

22. (New) The liposome of Claim 18 that comprises a multilamellar vesicle (MLV) structure.

B1 Cont

23. (New) The liposome of Claim 18 that comprises a small unilamellar vesicle (SUV) structure.

24. (New) A method for treating or preventing a brain disorder comprising administering and effective amount of the liposome of Claim 18 to a subject in need thereof.

REMARKS

Claims 5-24 are active. These claims find support in the original claims and disclosure. For instance, Claims 5-8 find support in original Claims 1-4 and in the specification on page 1, lines 4-11, and in the paragraph bridging pages 3 and 4. The nucleic acids and nucleic acid analogs of Claims 9-17 find support in the specification in the paragraph bridging pages 4 and 5 through the first paragraph on page 6. The liposomal products of Claims 18-24 find support in the specification on the last line of page 6, on page 7, starting at line 10 through line 17 of page 10. Accordingly, the Applicants do not believe that any new matter has been added. Favorable consideration of the amendment is respectfully requested.